Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

December 2023

Étude comparative en situation réelle de l'efficacité des inhibiteurs de Janus Kinase chez les patients atteints de polyarthrite rhumatoïde : L'étude de cohorte ANSWER

Rheumatology 2023 doi 10.1093/rheumatology/kead543

Maeda T,

Okano T,

Ueda Y,

Fujii T,

Hata K,

Yoshikawa A,

Ebina K,

Etani Y,

Amuro H,

Hara R,

Okano T,

This multicentre, retrospective study by Hayashi, et al. found no significant differences in efficacy and safety between tofacitinib, baricitinib, peficitinib and upadacitinib in patients with RA. Predictive factors for resistance to LDA achievement included baseline CRP and CDAI for tofacitinib and baseline glucocorticoid dose, baseline CDAI and number of previous b/tsDMARDs for baricitinib.

Keywords:

September 2023

Propriétés différentielles des inhibiteurs de Janus Kinase dans le traitement des maladies inflammatoires à médiation immunitaire

Rheumatology (Oxford) 2023;63(2):298–308 doi 10.1093/rheumatology/kead448

Choy E,

Lippe R,

JAKis differ in structure, which affects their inhibitory concentration for different JAKs.

This review by Taylor, et al. compares the pharmacological profiles of JAKis, including abrocitinib, baricitinib, filgotinib, peficitinib, tofacitinib, and upadacitinib.

Keywords:

July 2023

Analyse post hoc de patients atteints de polyarthrite rhumatoïde en rémission clinique dans deux essais du peficitinib de phase 3 au Japon (RAJ3 et RAJ4)

Mod Rheumatol 2023;34(3):453–65 doi: 10.1093/mr/road059

Kato D,

Pots hoc analysis of peficitinib Phase 3 trials shows that continued treatment with peficitinib up to Week 52 is linked to improved remission rates in Asian patients with RA.